These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7877530)

  • 41. [Fracture prevention and GH replacement therapy].
    Sugimoto T
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():587-93. PubMed ID: 16279706
    [No Abstract]   [Full Text] [Related]  

  • 42. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I.
    Kurland ES; Chan FK; Rosen CJ; Bilezikian JP
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2576-9. PubMed ID: 9661647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The dietary protein, IGF-I, skeletal health axis.
    Bonjour JP
    Horm Mol Biol Clin Investig; 2016 Oct; 28(1):39-53. PubMed ID: 26985688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Bone and hormones. Effects of growth hormone on bone tissue in adults].
    Chapurlat RD; Delmas PD
    Presse Med; 1999 Mar; 28(10):559-62. PubMed ID: 10209550
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promising new agents in osteoporosis.
    Reginster JY; Henrotin Y; Gosset C
    Drugs R D; 1999 Mar; 1(3):195-201. PubMed ID: 10566024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans.
    Wimalawansa SJ
    Ann N Y Acad Sci; 2007 Nov; 1117():283-97. PubMed ID: 18056048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of calcitonin in the development and treatment of osteoporosis.
    McDermott MT; Kidd GS
    Endocr Rev; 1987 Nov; 8(4):377-90. PubMed ID: 3319529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osteoporosis-bone remodeling and animal models.
    Bonucci E; Ballanti P
    Toxicol Pathol; 2014 Aug; 42(6):957-69. PubMed ID: 24285673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GH/IGF-I and bone resorption in vivo and in vitro.
    Ueland T
    Eur J Endocrinol; 2005 Mar; 152(3):327-32. PubMed ID: 15757846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis.
    Eriksen EF; Kassem M; Brixen K
    Horm Res; 1993; 40(1-3):95-8. PubMed ID: 8300056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6.
    Lou H; Kodama T; Wang YN; Katz N; Ramwell P; Foegh ML
    J Heart Lung Transplant; 1996 Dec; 15(12):1248-57. PubMed ID: 8981210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
    Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
    Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of bone loss after ovariectomy in mice with preferential overexpression of the transcription factor paired box-5 in osteoblasts.
    Fujita H; Hinoi E; Watanabe T; Iezaki T; Takamori M; Ogawa S; Yoneda Y
    Biol Pharm Bull; 2013; 36(3):481-4. PubMed ID: 23449333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Osteoporosis treatment in patients with hyperthyroidism].
    Saito J; Nishikawa T
    Nihon Rinsho; 2009 May; 67(5):1011-6. PubMed ID: 19432125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of growth hormone and sex steroids in achieving and maintaining normal bone mass.
    Holmes SJ; Shalet SM
    Horm Res; 1996; 45(1-2):86-93. PubMed ID: 8742125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.
    Bonjour JP; Kohrt W; Levasseur R; Warren M; Whiting S; Kraenzlin M
    Nutr Res Rev; 2014 Dec; 27(2):252-67. PubMed ID: 25394580
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short-term effects of growth hormone and insulin-like growth factor I on cancellous bone in rhesus macaque monkeys.
    Sass DA; Jerome CP; Bowman AR; Bennett-Cain A; Ginn TA; LeRoith D; Epstein S
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1202-9. PubMed ID: 9100597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral L-arginine before resistance exercise blunts growth hormone in strength trained males.
    Forbes SC; Harber V; Bell GJ
    Int J Sport Nutr Exerc Metab; 2014 Apr; 24(2):236-44. PubMed ID: 24225560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of glucocorticoid action in bone cells.
    Delany AM; Dong Y; Canalis E
    J Cell Biochem; 1994 Nov; 56(3):295-302. PubMed ID: 7876321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial.
    Erdtsieck RJ; Pols HA; Valk NK; van Ouwerkerk BM; Lamberts SW; Mulder P; Birkenhäger JC
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):557-65. PubMed ID: 8548940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.